273 related articles for article (PubMed ID: 30842316)
1. Activin type II receptor signaling in cardiac aging and heart failure.
Roh JD; Hobson R; Chaudhari V; Quintero P; Yeri A; Benson M; Xiao C; Zlotoff D; Bezzerides V; Houstis N; Platt C; Damilano F; Lindman BR; Elmariah S; Biersmith M; Lee SJ; Seidman CE; Seidman JG; Gerszten RE; Lach-Trifilieff E; Glass DJ; Rosenzweig A
Sci Transl Med; 2019 Mar; 11(482):. PubMed ID: 30842316
[TBL] [Abstract][Full Text] [Related]
2. Activin type II receptor ligand signaling inhibition after experimental ischemic heart failure attenuates cardiac remodeling and prevents fibrosis.
Castillero E; Akashi H; Najjar M; Ji R; Brandstetter LM; Wang C; Liao X; Zhang X; Sperry A; Gailes M; Guaman K; Recht A; Schlosberg I; Sweeney HL; Ali ZA; Homma S; Colombo PC; Ferrari G; Schulze PC; George I
Am J Physiol Heart Circ Physiol; 2020 Feb; 318(2):H378-H390. PubMed ID: 31886717
[TBL] [Abstract][Full Text] [Related]
3. Activin A and follistatin-like 3 determine the susceptibility of heart to ischemic injury.
Oshima Y; Ouchi N; Shimano M; Pimentel DR; Papanicolaou KN; Panse KD; Tsuchida K; Lara-Pezzi E; Lee SJ; Walsh K
Circulation; 2009 Oct; 120(16):1606-15. PubMed ID: 19805648
[TBL] [Abstract][Full Text] [Related]
4. Effects of the Activin A-Follistatin System on Myocardial Cell Apoptosis through the Endoplasmic Reticulum Stress Pathway in Heart Failure.
Liu M; Mao C; Li J; Han F; Yang P
Int J Mol Sci; 2017 Feb; 18(2):. PubMed ID: 28208629
[TBL] [Abstract][Full Text] [Related]
5. An activin mutant with disrupted ALK4 binding blocks signaling via type II receptors.
Harrison CA; Gray PC; Fischer WH; Donaldson C; Choe S; Vale W
J Biol Chem; 2004 Jul; 279(27):28036-44. PubMed ID: 15123686
[TBL] [Abstract][Full Text] [Related]
6. Antibody blockade of activin type II receptors preserves skeletal muscle mass and enhances fat loss during GLP-1 receptor agonism.
Nunn E; Jaiswal N; Gavin M; Uehara K; Stefkovich M; Drareni K; Calhoun R; Lee M; Holman CD; Baur JA; Seale P; Titchenell PM
Mol Metab; 2024 Feb; 80():101880. PubMed ID: 38218536
[TBL] [Abstract][Full Text] [Related]
7. Cripto forms a complex with activin and type II activin receptors and can block activin signaling.
Gray PC; Harrison CA; Vale W
Proc Natl Acad Sci U S A; 2003 Apr; 100(9):5193-8. PubMed ID: 12682303
[TBL] [Abstract][Full Text] [Related]
8. An antibody blocking activin type II receptors induces strong skeletal muscle hypertrophy and protects from atrophy.
Lach-Trifilieff E; Minetti GC; Sheppard K; Ibebunjo C; Feige JN; Hartmann S; Brachat S; Rivet H; Koelbing C; Morvan F; Hatakeyama S; Glass DJ
Mol Cell Biol; 2014 Feb; 34(4):606-18. PubMed ID: 24298022
[TBL] [Abstract][Full Text] [Related]
9. Novel factors in regulation of activin signaling.
Tsuchida K; Nakatani M; Matsuzaki T; Yamakawa N; Liu Z; Bao Y; Arai KY; Murakami T; Takehara Y; Kurisaki A; Sugino H
Mol Cell Endocrinol; 2004 Oct; 225(1-2):1-8. PubMed ID: 15451561
[TBL] [Abstract][Full Text] [Related]
10. Activin-A binds follistatin and type II receptors through overlapping binding sites: generation of mutants with isolated binding activities.
Harrison CA; Chan KL; Robertson DM
Endocrinology; 2006 Jun; 147(6):2744-53. PubMed ID: 16527838
[TBL] [Abstract][Full Text] [Related]
11. Activin receptor signaling regulates prostatic epithelial cell adhesion and viability.
Simon DP; Vadakkadath Meethal S; Wilson AC; Gallego MJ; Weinecke SL; Bruce E; Lyons PF; Haasl RJ; Bowen RL; Atwood CS
Neoplasia; 2009 Apr; 11(4):365-76. PubMed ID: 19308291
[TBL] [Abstract][Full Text] [Related]
12. Crystal structure of the WFIKKN2 follistatin domain reveals insight into how it inhibits growth differentiation factor 8 (GDF8) and GDF11.
McCoy JC; Walker RG; Murray NH; Thompson TB
J Biol Chem; 2019 Apr; 294(16):6333-6343. PubMed ID: 30814254
[TBL] [Abstract][Full Text] [Related]
13. Follistatin-like 3 mediates paracrine fibroblast activation by cardiomyocytes.
Panse KD; Felkin LE; López-Olañeta MM; Gómez-Salinero J; Villalba M; Muñoz L; Nakamura K; Shimano M; Walsh K; Barton PJ; Rosenthal N; Lara-Pezzi E
J Cardiovasc Transl Res; 2012 Dec; 5(6):814-26. PubMed ID: 22915069
[TBL] [Abstract][Full Text] [Related]
14. Systemic blockade of ACVR2B ligands attenuates muscle wasting in ischemic heart failure without compromising cardiac function.
Szabó Z; Vainio L; Lin R; Swan J; Hulmi JJ; Rahtu-Korpela L; Serpi R; Laitinen M; Pasternack A; Ritvos O; Kerkelä R; Magga J
FASEB J; 2020 Aug; 34(8):9911-9924. PubMed ID: 32427381
[TBL] [Abstract][Full Text] [Related]
15. Blockade of activin type II receptors with a dual anti-ActRIIA/IIB antibody is critical to promote maximal skeletal muscle hypertrophy.
Morvan F; Rondeau JM; Zou C; Minetti G; Scheufler C; Scharenberg M; Jacobi C; Brebbia P; Ritter V; Toussaint G; Koelbing C; Leber X; Schilb A; Witte F; Lehmann S; Koch E; Geisse S; Glass DJ; Lach-Trifilieff E
Proc Natl Acad Sci U S A; 2017 Nov; 114(47):12448-12453. PubMed ID: 29109273
[TBL] [Abstract][Full Text] [Related]
16. Activin subfamily peptides predict chronological age in humans.
Barrios-Silva LV; Parnell M; Shinwari ZB; Chaudhary GA; Xenofontos T; van Bekhoven A; McArthur S; Elliott BT
Physiol Rep; 2018 Sep; 6(17):e13823. PubMed ID: 30178598
[TBL] [Abstract][Full Text] [Related]
17. Effect of adenovirus-mediated overexpression of follistatin and extracellular domain of activin receptor type II on gonadotropin secretion in vitro and in vivo.
Leal AM; Takabe K; Wang L; Donaldson CJ; MacConell LA; Bilezikjian LM; Verma IM; Vale W
Endocrinology; 2002 Mar; 143(3):964-9. PubMed ID: 11861519
[TBL] [Abstract][Full Text] [Related]
18. Cardiac myocyte-specific ablation of follistatin-like 3 attenuates stress-induced myocardial hypertrophy.
Shimano M; Ouchi N; Nakamura K; Oshima Y; Higuchi A; Pimentel DR; Panse KD; Lara-Pezzi E; Lee SJ; Sam F; Walsh K
J Biol Chem; 2011 Mar; 286(11):9840-8. PubMed ID: 21245136
[TBL] [Abstract][Full Text] [Related]
19. Myeloid-Derived Growth Factor Protects Against Pressure Overload-Induced Heart Failure by Preserving Sarco/Endoplasmic Reticulum Ca
Korf-Klingebiel M; Reboll MR; Polten F; Weber N; Jäckle F; Wu X; Kallikourdis M; Kunderfranco P; Condorelli G; Giannitsis E; Kustikova OS; Schambach A; Pich A; Widder JD; Bauersachs J; van den Heuvel J; Kraft T; Wang Y; Wollert KC
Circulation; 2021 Oct; 144(15):1227-1240. PubMed ID: 34372689
[TBL] [Abstract][Full Text] [Related]
20. Long Noncoding RNA-DACH1 (Dachshund Homolog 1) Regulates Cardiac Function by Inhibiting SERCA2a (Sarcoplasmic Reticulum Calcium ATPase 2a).
Cai B; Zhang Y; Zhao Y; Wang J; Li T; Zhang Y; Jiang Y; Jin X; Xue G; Li P; Sun Y; Huang Q; Zhang X; Su W; Yang Y; Sun Y; Shi L; Li X; Lu Y; Yang B; Pan Z
Hypertension; 2019 Oct; 74(4):833-842. PubMed ID: 31446800
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
